6,818 Gilead Sciences, Inc. $GILD Shares Acquired by PBU The Pension Fund of Early Childhood & Youth Educators

PBU The Pension Fund of Early Childhood & Youth Educators lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 91,203 shares of the biopharmaceutical company’s stock after acquiring an additional 6,818 shares during the period. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Gilead Sciences were worth $13,594,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Client 1ST Advisory Group LLC raised its stake in Gilead Sciences by 4.0% during the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 69 shares during the period. Bfsg LLC grew its stake in shares of Gilead Sciences by 7.7% in the 3rd quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 72 shares during the period. Grove Bank & Trust increased its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 74 shares during the last quarter. Wilkerson Advisory Group LLC increased its holdings in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 78 shares during the last quarter. Finally, HBW Advisory Services LLC increased its holdings in shares of Gilead Sciences by 2.4% during the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock worth $473,000 after buying an additional 79 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, CEO Daniel O’Day sold 102,619 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the transaction, the chief executive officer owned 551,683 shares in the company, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This represents a 58.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 242,709 shares of company stock worth $39,503,427 in the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences News Summary

Investors following GILD have been watching these news items:

• Positive Sentiment: Results from the PURPOSE 5 trial showed twice-yearly injectable lenacapavir had better persistence than daily oral HIV-prevention medicines, with no HIV infections reported in the lenacapavir group. The data could strengthen the commercial outlook for Gilead’s prevention portfolio. Article: Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Negative Sentiment: Drug-price negotiations in Washington are cited as a near-term risk for Gilead, as lower prices could pressure revenue. The article does not quantify the potential impact. Article: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
• Negative Sentiment: Some valuation commentary argues Gilead may already be fully valued after substantial share-price gains, tempering enthusiasm despite recent trial results and raised guidance. Article: Gilead Sciences After Trial Wins And Raised Guidance Looks Fully Valued

Analyst Ratings Changes

A number of research firms recently commented on GILD. Sanford C. Bernstein reiterated an “outperform” rating and issued a $175.00 price objective on shares of Gilead Sciences in a report on Monday, November 2nd. Citigroup raised their target price on Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Argus set a $190.00 target price on Gilead Sciences in a research report on Thursday. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a research note on Friday, October 30th. Finally, Morgan Stanley increased their price target on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $171.07.

Gilead Sciences Stock Down 1.0%

Gilead Sciences stock opened at $167.95 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The firm has a 50 day moving average price of $154.76 and a 200 day moving average price of $141.66. The company has a market capitalization of $208.31 billion, a PE ratio of -53.15 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the prior year, the firm earned $2.47 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post -0.98 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 2.0%. Gilead Sciences’s dividend payout ratio is presently -103.80%.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.